Mirum Pharmaceuticals, Inc.

This study tests whether switching from the current drug bulevirtide to a new one called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug and be monitored for 24 weeks. The main goal is…

This study looks at the long-term safety and effectiveness of the drug Livmarli in people with Alagille syndrome, a rare genetic liver condition. About 100 patients who are already prescribed Livmarli will be followed to monitor side effects, liver function, and key health outcom…

This study tests a new medicine called brelovitug for people with chronic hepatitis delta, a serious liver infection. About 80 adults will either get the drug right away or wait a few weeks before starting it. The goal is to see if brelovitug can lower the virus level and improve…

This study tests a new medicine, BJT-778, against an existing one, bulevirtide, for people with chronic hepatitis delta, a serious liver infection. About 172 adults will receive either drug for long-term control of the virus. The goal is to see if BJT-778 can better lower virus l…

This study tests an experimental drug called volixibat to see if it can reduce the intense itching caused by primary biliary cholangitis (PBC). About 260 adults with PBC and moderate-to-severe itching will receive either volixibat or a placebo. The main goal is to measure changes…

This study tests a new drug called MRM-3379 in males aged 13 to 45 with Fragile X Syndrome. The goal is to see if the drug is safe and can improve symptoms. Participants will take the drug or a placebo for 12 weeks. The study is currently recruiting 60 people.